Pathology of Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) represents a unique subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. This track will delve into the intricate pathology of TNBC, exploring its clinical implications and therapeutic strategies. Attendees will gain insights into the aggressive nature of TNBC, its distinct molecular features, and the challenges associated with diagnosis and treatment. Discussion will focus on emerging biomarkers, novel targeted therapies, and immunotherapy approaches. By understanding the underlying pathology of TNBC, participants will be equipped to optimize patient management, improve prognostic evaluation, and contribute to the development of personalized therapeutic interventions.

 

 

    Related Conference of Pathology of Triple-Negative Breast Cancer

    April 28-29, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain

    Pathology of Triple-Negative Breast Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in